Postmenopausal Osteoporosis: How to Prep for Your First Visit

What Postmenopausal Osteoporosis Actually Is

Postmenopausal osteoporosis is a systemic skeletal disease defined by low bone mineral density (BMD) and deteriorating bone architecture that raises fracture risk. The mechanism is direct: estrogen normally restrains osteoclast (bone-resorbing cell) activity. When estrogen drops after menopause, osteoclasts become overactive and outpace osteoblasts (bone-forming cells), creating a net bone deficit.

Bone loss in postmenopausal women averages 1-2% per year overall, but in the trabecular bone of the spine, loss can reach 3-5% annually during the first 5-7 postmenopausal years [1]. Cortical bone in the hip follows a slower but still significant trajectory.

Why Women Bear a Disproportionate Burden

Men lose bone too, but more slowly, and they start from a higher peak bone mass baseline. Women also live longer, giving bone loss more time to accumulate. By age 80, approximately 70% of white women meet BMD criteria for osteoporosis or its precursor, osteopenia [2]. Black and Hispanic women have higher baseline BMD on average but are not immune, and they are often underscreened.

The Fracture Is the Problem

A T-score number alone is not the clinical emergency. A fragility fracture, meaning a break from a force that would not normally break a bone, like stepping off a curb, is the real harm. Hip fractures carry a 20-24% one-year mortality rate in older women [3], and vertebral fractures cause chronic back pain, height loss, and breathing restriction from rib-cage compression.

Who Should Be Screened and When

The U.S. Preventive Services Task Force (USPSTF) recommends BMD screening for all women aged 65 and older [4] using DEXA. For women under 65 who have gone through menopause, screening is recommended when their 10-year fracture probability on the FRAX tool equals or exceeds that of a 65-year-old white woman with no additional risk factors, which is approximately 9.3%.

Risk Factors That Move Up Your Screening Date

You should ask for a DEXA before age 65 if you have any of the following:

• Early menopause (before age 45) or surgical menopause
• Long-term glucocorticoid use (prednisone 5 mg or more daily for 3 or more months)
• Low body weight (BMI <19)
• Personal history of fragility fracture
• Parent with a hip fracture
• Rheumatoid arthritis
• Current smoking
• Secondary causes of bone loss: primary hyperparathyroidism, celiac disease, eating disorders, or prolonged amenorrhea from hypothalamic dysfunction

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 129 [5] aligns with USPSTF thresholds but also flags that women with premature ovarian insufficiency (POI) need early bone assessment because they lose estrogen support decades ahead of natural menopause.

Life Stage Breakdown

Perimenopause: Bone loss begins here, years before the final menstrual period. If you are perimenopausal and have risk factors, ask your provider about a baseline DEXA now rather than waiting.

Early postmenopause (0-5 years): The highest rate of bone loss. This is the window where intervention has the most impact on trajectory.

Late postmenopause (10+ years): Bone loss continues but slows. Fracture risk accumulates from the years of prior deficit. Hip fracture risk rises steeply after age 70.

The DEXA Scan: What It Is and How to Read Your Results

A DEXA scan is a low-radiation X-ray that measures BMD at the lumbar spine (L1-L4), total hip, and femoral neck. The test takes about 10-20 minutes, requires no contrast, and exposes you to roughly 1-6 microsieverts of radiation, less than a chest X-ray [6].

Reading Your T-Score

| T-Score | Interpretation | |---|---| | Above -1.0 | Normal bone density | | -1.0 to -2.4 | Osteopenia (low bone mass) | | -2.5 or below | Osteoporosis | | -2.5 or below plus fracture | Severe osteoporosis |

The T-score compares your BMD to the average peak bone mass of a young adult woman. Your Z-score compares you to age-matched peers; a Z-score below -2.0 suggests a secondary cause of bone loss beyond menopause alone.

The FRAX Tool: Beyond the T-Score

Your T-score does not tell the whole story. A woman with a T-score of -2.0 who has had a prior fragility fracture has a very different 10-year fracture probability than one with the same T-score and no risk factors. The FRAX tool, developed by the University of Sheffield and validated in large international cohorts [7], integrates BMD with age, weight, height, smoking, alcohol use, steroid use, prior fracture, parent hip fracture, rheumatoid arthritis, and secondary osteoporosis causes to produce a 10-year fracture probability.

The National Osteoporosis Foundation (NOF) and The Menopause Society both recommend using FRAX to guide treatment decisions [8]. Treatment is generally recommended when FRAX shows a 10-year major osteoporotic fracture probability of 20% or more, or a hip fracture probability of 3% or more.

Preparing for Your First Visit: A Practical Checklist

Walking into your first bone-health appointment prepared makes a measurable difference in what you get out of it. Here is what to do in the days before.

Documents and Records to Bring

• Any prior DEXA reports (even from years ago; the change over time matters)
• Recent blood work: calcium, vitamin D (25-OH), thyroid-stimulating hormone, complete metabolic panel
• A full medication list, including supplements, because calcium supplements, proton pump inhibitors, and thyroid medications all affect bone
• Family history notes: maternal or paternal hip or spine fracture, early menopause in female relatives
• A 3-day food record or a rough estimate of your daily calcium intake from food

Questions to Ask Your Provider

Your first visit will move fast. Write these down:

1. What is my T-score at each site, and what does that mean for my fracture risk?
2. What is my FRAX 10-year fracture probability?
3. Do I need additional bloodwork to rule out secondary causes of bone loss?
4. Should I start medication now, or can I address this with lifestyle changes first?
5. If medication is recommended, why this drug over alternatives, and what are the risks specific to women?
6. How long will I be on this medication, and what happens when I stop?
7. How often will I repeat a DEXA scan to track progress?
8. Are there interactions with my current medications or supplements?

What Your Provider Will Likely Assess

Your first visit will generally include a physical exam (height measurement is standard because height loss flags vertebral fractures), a review of fall risk, assessment of muscle strength and balance, and possibly a vertebral fracture assessment (VFA), a low-dose lateral spine image that can be done on most modern DEXA machines.

Lab work ordered at or around the first visit typically includes:

• Serum 25-hydroxyvitamin D
• Serum calcium and phosphorus
• Complete blood count
• Comprehensive metabolic panel (renal and liver function)
• Thyroid-stimulating hormone
• Parathyroid hormone (PTH) if calcium is abnormal
• Urine calcium-to-creatinine ratio

A serum protein electrophoresis may be ordered if multiple myeloma needs to be ruled out in a woman with unexpectedly severe bone loss.

Treatment Options Your Provider May Discuss

Treatment decisions depend on your T-score, FRAX score, prior fractures, age, other health conditions, and personal preferences. Here is a plain-language summary of what is available.

Calcium and Vitamin D: Foundation, Not Treatment

Both are necessary but neither treats established osteoporosis on their own. The Menopause Society recommends 1,200 mg of elemental calcium daily from all sources combined for postmenopausal women [9], ideally from food, with supplements filling gaps. Vitamin D sufficiency requires a serum 25-OH level of at least 30 ng/mL [10]; most women in northern latitudes need 1,000-2,000 IU of vitamin D3 daily to maintain that threshold.

Calcium carbonate is cheapest but requires stomach acid for absorption, so take it with food. Calcium citrate does not require acid and suits women on proton pump inhibitors.

Bisphosphonates: First-Line Oral Therapy

Alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva) are the most commonly prescribed first-line agents. They work by inhibiting osteoclasts, reducing bone resorption.

Alendronate 70 mg once weekly reduces vertebral fracture risk by approximately 47% and hip fracture risk by 51% compared to placebo, from the FIT trial [11]. Zoledronic acid (Reclast) is an annual IV infusion that achieves similar results for women who cannot tolerate oral tablets, with the HORIZON-PFT trial showing a 41% reduction in hip fracture and 70% reduction in vertebral fracture over 3 years [12].

Oral bisphosphonates must be taken fasting, with a full glass of plain water, and you must remain upright for at least 30 minutes to reduce the risk of esophageal irritation. Women with creatinine clearance below 35 mL/min should not use bisphosphonates.

Rare but serious risks include osteonecrosis of the jaw (ONJ, estimated risk approximately 1 in 10,000 to 1 in 100,000 in osteoporosis patients) and atypical femoral fractures after long-term use. For most women, a 3-5 year oral bisphosphonate course or 3-year IV zoledronic acid course is appropriate, followed by a reassessment and possible drug holiday.

Denosumab: For Women Who Cannot Use Bisphosphonates

Denosumab (Prolia) is a monoclonal antibody given as a subcutaneous injection every 6 months. It inhibits RANKL, a protein that activates osteoclasts. The FREEDOM trial showed a 68% reduction in vertebral fracture and 40% reduction in hip fracture over 3 years [13].

A critical clinical point for women considering denosumab: you cannot simply stop it. Discontinuing denosumab without transitioning to another antiresorptive causes a rapid rebound in bone turnover and rebound vertebral fractures, sometimes multiple, within 12-18 months. This must be discussed in full at your first visit.

Hormone Therapy: The Estrogen Option

Menopausal hormone therapy (MHT, also called HRT) prevents bone loss by replacing the estrogen that drove the deficit in the first place. The Women's Health Initiative (WHI) conjugated equine estrogen plus medroxyprogesterone arm showed a 34% reduction in hip fracture and 34% reduction in vertebral fracture [14] compared to placebo.

The Menopause Society's 2023 position statement [15] affirms that for women under 60 or within 10 years of menopause onset who have bothersome symptoms, MHT is a reasonable approach with an acceptable risk profile, and bone protection is an added benefit. MHT is not typically used as osteoporosis treatment in women over 60 or more than a decade past menopause without symptom indication, largely due to cardiovascular and breast considerations.

Anabolic Options: For Severe Disease

Teriparatide (Forteo), abaloparatide (Tymlos), and romosozumab (Evenity) are reserved for women with severe osteoporosis (very low T-scores or multiple fractures) or those who have fractured on antiresorptive therapy.

Romosozumab is a dual-action monoclonal antibody that both builds bone and reduces resorption. The ARCH trial showed romosozumab followed by alendronate reduced new vertebral fracture risk by 48% over 24 months compared to alendronate alone [16], but romosozumab carries a boxed warning for increased cardiovascular event risk and should not be used in women with a history of heart attack or stroke.

Pregnancy, Lactation, and Contraception Considerations

Most osteoporosis medications carry significant warnings for use during pregnancy, and women of reproductive age who are prescribed them need a clear plan.

Bisphosphonates incorporate into bone and can remain in the skeleton for years. Animal studies show fetal harm at high doses, and while human data are limited, bisphosphonates are not recommended in pregnancy [17]. For a premenopausal woman prescribed alendronate or zoledronic acid, effective contraception is required for the duration of treatment. Because bisphosphonates persist in bone, some experts advise waiting 12 months or more after stopping before attempting conception, though definitive human safety data are lacking.

Denosumab is classified FDA Pregnancy Category X based on animal data showing fetal harm. Effective contraception is mandatory during treatment and for at least 5 months after the last dose.

Teriparatide and abaloparatide are not recommended in pregnancy; animal studies show skeletal abnormalities.

Romosozumab is contraindicated in pregnancy based on animal reproductive toxicity data.

Menopausal hormone therapy is not appropriate during pregnancy. For women in true postmenopause, pregnancy is not a concern, but for perimenopausal women started on MHT who may still ovulate irregularly, contraception is still recommended for the first 12 months after the last natural period if under age 50, or 6 months if over 50.

Lactation: Bone loss during breastfeeding is physiological (up to 5% over 6 months) and typically reverses spontaneously within 6-12 months of weaning. This postpartum bone loss does not appear to permanently increase fracture risk [18] in otherwise healthy women. Bisphosphonates, denosumab, and anabolic agents are all contraindicated while breastfeeding due to insufficient safety data and known risks from animal studies.

Who This Approach Is Right For (and Who Needs a Different Plan)

Not every woman diagnosed with a low T-score needs the same path. Here is a life-stage framework for thinking through where you stand.

Women Most Likely to Benefit from Medication at Diagnosis

• FRAX major fracture probability at or above 20%, or hip fracture probability at or above 3%
• T-score at or below -2.5 at any measured site
• Prior fragility fracture at any site (this alone meets treatment threshold regardless of T-score)
• T-score between -1.0 and -2.5 with high FRAX probability or secondary cause of bone loss

Women Who May Watch and Wait with Lifestyle

• Early postmenopausal women with T-scores in osteopenia range (-1.0 to -2.4), low FRAX probability, no prior fractures, no secondary causes
• Women who want to address modifiable risk factors (smoking cessation, alcohol reduction, resistance exercise, fall prevention) before committing to medication

Women Needing Specialist Referral Beyond a General Visit

• Unexpectedly severe bone loss for age (Z-score below -2.0) suggesting a secondary cause
• History of multiple fragility fractures despite prior treatment
• Renal impairment limiting bisphosphonate use
• Prior breast cancer or endometrial cancer affecting hormone therapy eligibility
• Very young age of diagnosis (premenopausal or early perimenopausal with T-scores meeting osteoporosis criteria)

Lifestyle Changes With Real Evidence Behind Them

Medication works best with a physical foundation. These are the interventions with the clearest evidence in postmenopausal women.

Weight-Bearing and Resistance Exercise

The LIFTMOR trial in postmenopausal women with low to very low bone mass showed that high-intensity progressive resistance and impact training increased lumbar spine BMD by 2.9% and femoral neck BMD by 0.3% compared to a control low-intensity program [19]. This is meaningful: supervised, progressively loaded resistance training is not optional for bone health. Aim for at least 2-3 sessions per week with exercises that include deadlifts, squats, and impact movements unless contraindicated by other joint conditions.

Walking alone is not sufficient for spine or hip bone protection, though it helps with fall risk through balance and muscle conditioning.

Fall Prevention

A fragility fracture requires both low bone density and a fall. Each year, approximately 30% of adults over 65 fall, and falls account for the majority of hip fractures [20]. At your first visit, your provider may refer you to a physical therapist for balance training (Otago or similar programs reduce fall rate by 30-35%). Home hazard assessment, reviewing medications that increase fall risk (sedatives, blood pressure medications), and vision correction also belong in the plan.

Smoking and Alcohol

Smoking reduces BMD by a direct toxic effect on osteoblasts and by lowering estrogen levels. Alcohol above 2 drinks daily is an independent risk factor for fracture. Both are modifiable, and your provider should address them without judgment at your first visit.

After the First Visit: What Monitoring Looks Like

Osteoporosis is a chronic condition, not a one-appointment diagnosis. Here is what you can expect going forward.

A repeat DEXA scan is typically performed every 1-2 years while on treatment to assess response [5], or every 2 years during a drug holiday. Bone turnover markers (serum C-telopeptide, procollagen type 1 N-terminal propeptide) are sometimes used between DEXA scans to confirm the medication is working within 3-6 months of starting treatment.

If your T-score improves by less than the least significant change on DEXA (typically 0.03-0.04 g/cm2 at most centers), your provider will want to assess adherence, calcium and vitamin D adequacy, and potential secondary causes before changing treatment.

"The conversation at a woman's first osteoporosis visit should cover not just what her T-score is, but why her bone is where it is, what her real fracture probability is over the next decade, and exactly what the first 12 months of treatment will look like, including what happens if she needs to stop," says Rachel Goldberg, MD, WomanRx Medical Reviewer and board-certified OB-GYN with a women's health focus. "Women who understand the mechanism are far more likely to stay adherent to treatments that feel invisible."

One more number worth knowing: adherence to oral bisphosphonates at one year is estimated at only 40-60% [21], largely because the dosing ritual is inconvenient and the drug is doing work you cannot feel. If adherence is a concern for you, tell your provider at the first visit. IV zoledronic acid, given once a year, may suit you better than a weekly oral tablet.